Immunogenicità, sicurezza e tollerabilità del vaccino RF1V-1018 negli adulti dai 18 ai 55 anni di età
Fase 2, studio randomizzato, multicentrico di immunogenicità, sicurezza e tollerabilità del vaccino RF1V-1018 negli adulti dai 18 ai 55 anni di età
This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
This dose-finding study will evaluate the immunogenicity, safety, and tolerability of multiple doses and regimens of rF1V-1018 vaccine in healthy adults. Immunogenicity blood samples will be drawn at several timepoints during the study. Participants will return to the clinic for periodic visits for study specific evaluations including evaluation of immunogenicity and safety. Safety assessments will be done at regular intervals through the end of the trial.
Six dose regimens will be tested in Part 1 of the study. Up to two dose regimens from Part 1 will be chosen for Part 2 of the study.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Florida
-
Miami, Florida, Stati Uniti, 33172
- 103
-
-
Kansas
-
El Dorado, Kansas, Stati Uniti, 67042
- AMR- El Dorado
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 889119
- AMR- Las Vegas
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45212
- CTI Clinical Research Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults 18 to 55 years of age
- Healthy participants or participants with stable pre-existing medical conditions Pre-existing stable medical condition means a participant who: has full capacity of daily activity and no major medication modification within 3 months prior to Day 1; has not undergone surgical or minimally-invasive intervention or had any hospitalization/emergency room visit for the specific medical condition.
- Able to comply with the protocol schedule and procedures
- Able and willing to provide written informed consent
- If female of child-bearing potential and heterosexually active, has practiced adequate contraception for at least 28 days prior to vaccination, has negative pregnancy tests just prior to vaccination, and has agreed to continue adequate contraception through three months following the final trial injection
A premenopausal woman who has at least one of the following is considered not of childbearing potential:
- Documented hysterectomy
- Documented bilateral salpingectomy
- Documented bilateral oophorectomy
- Documented and current bilateral tubal ligation or occlusion
Exclusion Criteria:
-
A history of plague disease or have previously received any plague vaccine
-
Active tuberculosis or other systemic infectious process
-
History of human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) infection, or positive test for antibody to HIV, HBV, or HCV
-
History of autoimmune disorder
-
History of sensitivity to any component of trial vaccines
-
Body mass index ≥ 30 kg/m2
-
Has received the following prior to any trial injection:
a) ≤ 14 days: i) Any licensed or authorized inactivated vaccines (including vaccines containing mRNA or CpG) b) ≤ 28 days: i) Any live vaccine ii) Any investigational medicinal agent c) ≤ 90 days: i) Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first trial vaccine administration or planned administration during the trial period. (For corticosteroids, this will mean prednisone ≥20 mg/day, or equivalent). Inhaled, topical, and intraarticular steroids are allowed.
ii) Granulocyte or granulocyte-macrophage colony stimulating factor iii) Immunoglobulins or any blood products (receipt of certain monoclonal antibodies may on a case-by-case basis be non-exclusionary if approved via consultation with Sponsor Medical Monitor) iv) Antisense oligonucleotides v) Drugs/investigational agents with very long half-lives (defined as ≥ 60 days) (eg, radioactive iodine, amiodarone, liraglutide, nirsevimab, teplizumab, evinacumab, and obinutuzumab) vi) Infusion of blood products d) At any time: DNA plasmids or other genetic therapy intended to integrate permanently into host cells
-
If female is pregnant (known before or established at the time of screening), breastfeeding, or planning breastfeeding or a pregnancy
-
Is undergoing chemotherapy or expected to receive chemotherapy during the trial period; has a diagnosis of cancer within the last 5 years other than squamous cell or basal cell carcinoma of the skin
-
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
-
Oral temperature ≥ 38°C (≥ 100.4°F) at the time of vaccine administration
-
History of acute myocardial infarction (AMI) or documented coronary artery disease (CAD)
-
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Part 1 Arm 1
|
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
Sperimentale: Part 1 Arm 2
|
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
Sperimentale: Part 1 Arm 5
|
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
Sperimentale: Part 1 Arm 6
|
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
Sperimentale: Part 1 and Part 2: Arm 3
This Part 1 arm was selected for Part 2. |
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
Sperimentale: Part 1 and Part 2: Arm 4
This Part 1 arm was selected for Part 2. |
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Livello di anticorpi anti-RF1V
Lasso di tempo: 4 settimane dopo il vaccino da studio finale
|
4 settimane dopo il vaccino da studio finale
|
|
|
Evaluate safety of rF1V-1018
Lasso di tempo: injection reactions through 7 days after each study vaccine, adverse events for 28 days after each study vaccine; SAEs, MAEs, imAESIs through 6 months after the final study vaccine
|
Evaluate adverse events |
injection reactions through 7 days after each study vaccine, adverse events for 28 days after each study vaccine; SAEs, MAEs, imAESIs through 6 months after the final study vaccine
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- DV2-DC02-02
- VCG26632 (Altro identificatore: Sanofi)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .